Biosimilars: The Unlikely Hero Of Specialty Pharma?
Executive Summary
In the patent cliff musical chairs game, the music has stopped and generic companies like Mylan and Teva are looking for the next growth driver. While this seems to be biosimilars, it appears that innovator companies who are used to developing biologics, are already sitting in their seats.
You may also be interested in...
Shire Exits Biosimilars, Streamlines Oncology Business
Terminating a pair of biosimilar partnerships inherited from Baxalta will better enable Shire to focus on core strengths, CEO Ornskov says. The firm will use Baxalta assets to gradually develop a cancer franchise.
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.
Boehringer Ingelheim Throws Its Humira Biosimilar Hat Into The Ring
Boehringer Ingelheim is poised to submit marketing applications in the US and Europe for its biosimilar adalimumab after it showed equivalent safety and efficacy to Humira in a pivotal study.